// Biotech and Pharma Therapeutics EyePoint sees stock surge on AMD drug trial data December 4, 2023 / Eyepoint / Drug Trial Data / Mid-stage Study / Eye Disease EyePoint’s medicine, called vorolanib, matched the performance of Regeneron’s top-selling drug...